Table 5.

Complications and outcomes of forty-two COVID-19 patients and forty-three non-COVID-19 patients with acute respiratory distress syndrome.

Characteristic	COVID-19 patients with ARDS (n = 42)	Non-COVID-19 patients with ARDS (n = 43)	P-value
Mechanical ventilation (days)	19.5 (12.4–24.1)	21.6 (15.9–27.3)	0.004*
Survivors (days)	16.8 (12.6–21.0)	21.3 (16.5–25.7)	<0.001*
ICU length of stay (days)	21.5 (17.3–28.3)	27.8 (18.2–31.9)	0.001*
Survivors (days)	21.2 (16.4–26.0)	26.0 (19.5–32.4)	0.002*
Hospital length of stay (days)	30.8 (22.9–37.3)	33.2 (27.8–44.8)	0.001*
Acute kidney injury, n (%)	4 (9.5)	7 (8.2)	0.35
Pulmonary embolism, n (%)	15 (35.7)	4 (9.3)	0003*
60-day mortality, n (%)	15 (35.7%)	6 (14%)	0.02*

ICU, intensive care unit. Acute Kidney Injury as defined by the RIFLE criteria.

^*P-values ≤ 0.05 were statistically significant (comparisons between the COVID-19 vs. the non-COVID-19 group of patients).